ACCE price target published on 22 Oct 2026, 16:00 CEST.
Price used: ¥2818 at the close on 23 Oct 2026, 08:30 CEST.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
56
out of 100
P/E
21.3x
forward 19.6x
1-year return
-30.6%
Dividend yield
3.53%
Daiichi Sankyo Company, Limited in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Daiichi Sankyo is a Tokyo-listed drugmaker whose antibody-drug conjugates (ADCs), including the Enhertu franchise co-developed with AstraZeneca, carry most of its growth and its pipeline value. Its edge is proprietary ADC linker and payload technology, which is hard to replicate and has earned it a durable position in oncology partnerships. The near-term driver is continued uptake of Enhertu across additional HER2-expressing tumour types, with revenue growing 21.1% over the latest reported period, a pace well above what most large-cap pharma peers manage. At 19.8x forward earnings against 21.5x trailing, the market is already pricing in some of that growth, though the 68.5% gross margin and 14.8% operating margin leave room for the earnings base to expand as product sales scale. The question for the team is how much of the Enhertu royalty and milestone economics is locked in versus dependent on future label expansions, and whether the rest of the pipeline can offset any slowdown in that franchise.
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
high
Earnings declining despite revenue growth
Revenue rose 21.1% year on year, but earnings fell 18.1%, and the latest quarter missed EPS estimates by 12.0%. Margins are not keeping pace with sales.
moderate
Negative free cash flow
Free cash flow is reported at JPY-equivalent $-192.9bn, a large negative figure that needs checking against the filings before weighting the position.
AI research notes
AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-10-22 · prices to Oct 23, 2026
Why it could do well
Revenue grew 21.1% year over year, and the five-year average annual growth rate is 35.2%.
Analysts' mean price target of JPY 4027.50 sits 42.0% above the current share price.
The dividend yield of 3.5% pays shareholders while they wait for the growth to show up in earnings.
Why it could disappoint
Free cash flow over the last 12 months was negative at -JPY 192.9B, so the growth is consuming cash rather than producing it.
The latest earnings per share missed expectations by 12.0%, coming in at 37.72 against 42.86 expected.
Return on equity of 14.8% and a net margin of 10.9% are modest for a company priced at 21.5 times trailing earnings.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where 4568.T's valuation models land
Price
¥2817.50
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores
+Score history: how each score moved over time
Analysts
Wall Street consensus
No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
+Price-target low / average / high vs the current price, with implied upside
+Forward revenue and EPS consensus by fiscal year
+ACCE fair-value models lined up against the Street
Smart Money
PRO
In one line
Trades are only made public after a delay. We show the delay so you know how old the news is.